N-(2,3-dichlorophenyl)cyclohexanecarboxamide
N-(2,3-dichlorophenyl)cyclohexanecarboxamide structure
|
Common Name | N-(2,3-dichlorophenyl)cyclohexanecarboxamide | ||
|---|---|---|---|---|
| CAS Number | 200709-97-3 | Molecular Weight | 272.170 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 429.3±35.0 °C at 760 mmHg | |
| Molecular Formula | C13H15Cl2NO | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 213.4±25.9 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Similarities and Distinctions in Actions of Surface-Directed and Classic Androgen Receptor Antagonists.
PLoS ONE 10(9) , e0137103, (2015) The androgen receptor (AR) surface-directed antagonist MJC13 inhibits AR function and proliferation of prostate cancer (PC) cells. These effects are related to arrest of an AR/chaperone complex in the cytoplasm. Here, we compared MJC13 and classic AR antagoni... |
|
|
The FKBP52 Cochaperone Acts in Synergy with β-Catenin to Potentiate Androgen Receptor Signaling.
PLoS ONE 10(7) , e0134015, (2015) FKBP52 and β-catenin have emerged in recent years as attractive targets for prostate cancer treatment. β-catenin interacts directly with the androgen receptor (AR) and has been characterized as a co-activator of AR-mediated transcription. FKBP52 is a positive... |
|
|
Quantification of a New Anti-Cancer Molecule MJC13 Using a Rapid, Sensitive, and Reliable Liquid Chromatography-Tandem Mass Spectrometry Method.
Am. J. Mod. Chromatogr. 1(1) , 1-11, (2014) MJC13 is a novel molecule that has potential use for the treatment of hormone refractory prostate cancer (HRPC). The purpose of this work was to develop a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for quantification of MJC13. Itraconazo... |
|
|
Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression.
Steroids 78(6) , 548-54, (2013) Androgen ablation therapy is the most common treatment for advanced prostate cancer (PCa), but most patients will develop castration-resistant prostate cancer (CRPC), which has no cure. CRPC is androgen-depletion resistant but androgen receptor (AR) dependent... |
|
|
Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells.
Proc. Natl. Acad. Sci. U. S. A. 108(29) , 11878-83, (2011) Drugs that target novel surfaces on the androgen receptor (AR) and/or novel AR regulatory mechanisms are promising alternatives for the treatment of castrate-resistant prostate cancer. The 52 kDa FK506 binding protein (FKBP52) is an important positive regulat... |
|
|
Solution formulation development and efficacy of MJC13 in a preclinical model of castration-resistant prostate cancer.
Pharm. Dev. Technol. 21(1) , 121-6, (2016) MJC13, a novel FKBP52 targeting agent, has potential use for the treatment of castration-resistant prostate cancer. The purpose of this work was to develop a solution formulation of MJC13, and obtain its efficacy profile in a human prostate cancer xenograft m... |